kynurenine has been researched along with Fatty Liver in 5 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The hyperglycemia was accompanied with decreased insulin levels, which may have been due to the repression of genes involved in insulin secretion." | 5.62 | Kynurenine-Induced Aryl Hydrocarbon Receptor Signaling in Mice Causes Body Mass Gain, Liver Steatosis, and Hyperglycemia. ( Chamberlin, MD; Coker, S; Lewis, LD; Moyer, BJ; Ness, DB; Pooler, DB; Ringelberg, CS; Rojas, IY; Tomlinson, CR; Tosteson, TD; Wilkins, OM, 2021) |
| "Obesity is an increasingly urgent global problem, yet, little is known about its causes and less is known how obesity can be effectively treated." | 5.43 | Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1. ( Collins, AJ; Gimi, B; Hazlett, HF; Kerley-Hamilton, JS; Kinlaw, WB; Lupien, LE; Moyer, BJ; Nemani, KV; Ringelberg, CS; Rojas, IY; Tomlinson, CR; Trask, HW; West, RJ, 2016) |
| "The hyperglycemia was accompanied with decreased insulin levels, which may have been due to the repression of genes involved in insulin secretion." | 1.62 | Kynurenine-Induced Aryl Hydrocarbon Receptor Signaling in Mice Causes Body Mass Gain, Liver Steatosis, and Hyperglycemia. ( Chamberlin, MD; Coker, S; Lewis, LD; Moyer, BJ; Ness, DB; Pooler, DB; Ringelberg, CS; Rojas, IY; Tomlinson, CR; Tosteson, TD; Wilkins, OM, 2021) |
| "Obesity is an increasingly urgent global problem, yet, little is known about its causes and less is known how obesity can be effectively treated." | 1.43 | Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1. ( Collins, AJ; Gimi, B; Hazlett, HF; Kerley-Hamilton, JS; Kinlaw, WB; Lupien, LE; Moyer, BJ; Nemani, KV; Ringelberg, CS; Rojas, IY; Tomlinson, CR; Trask, HW; West, RJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, KM | 1 |
| Tint, MT | 1 |
| Kothandaraman, N | 1 |
| Yap, F | 1 |
| Godfrey, KM | 1 |
| Lee, YS | 1 |
| Tan, KH | 1 |
| Gluckman, PD | 1 |
| Chong, YS | 1 |
| Chong, MFF | 1 |
| Eriksson, JG | 1 |
| Cameron-Smith, D | 1 |
| Rojas, IY | 2 |
| Moyer, BJ | 2 |
| Ringelberg, CS | 2 |
| Wilkins, OM | 1 |
| Pooler, DB | 1 |
| Ness, DB | 1 |
| Coker, S | 1 |
| Tosteson, TD | 1 |
| Lewis, LD | 1 |
| Chamberlin, MD | 1 |
| Tomlinson, CR | 2 |
| Laurans, L | 1 |
| Venteclef, N | 1 |
| Haddad, Y | 1 |
| Chajadine, M | 1 |
| Alzaid, F | 1 |
| Metghalchi, S | 1 |
| Sovran, B | 1 |
| Denis, RGP | 1 |
| Dairou, J | 1 |
| Cardellini, M | 1 |
| Moreno-Navarrete, JM | 1 |
| Straub, M | 1 |
| Jegou, S | 1 |
| McQuitty, C | 1 |
| Viel, T | 1 |
| Esposito, B | 1 |
| Tavitian, B | 1 |
| Callebert, J | 1 |
| Luquet, SH | 1 |
| Federici, M | 1 |
| Fernandez-Real, JM | 1 |
| Burcelin, R | 1 |
| Launay, JM | 1 |
| Tedgui, A | 1 |
| Mallat, Z | 1 |
| Sokol, H | 1 |
| Taleb, S | 1 |
| Kerley-Hamilton, JS | 1 |
| Hazlett, HF | 1 |
| Nemani, KV | 1 |
| Trask, HW | 1 |
| West, RJ | 1 |
| Lupien, LE | 1 |
| Collins, AJ | 1 |
| Gimi, B | 1 |
| Kinlaw, WB | 1 |
| Osawa, Y | 1 |
| Kanamori, H | 1 |
| Seki, E | 1 |
| Hoshi, M | 1 |
| Ohtaki, H | 1 |
| Yasuda, Y | 1 |
| Ito, H | 1 |
| Suetsugu, A | 1 |
| Nagaki, M | 1 |
| Moriwaki, H | 1 |
| Saito, K | 1 |
| Seishima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Very Low Calorie Ketogenic Diet on Microbiota, Adipose Tissue and Immunitary Regulation: Pilot Study on Patients With Metabolic Syndrome[NCT05275608] | 40 participants (Anticipated) | Interventional | 2022-11-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for kynurenine and Fatty Liver
| Article | Year |
|---|---|
Association of plasma kynurenine pathway metabolite concentrations with metabolic health risk in prepubertal Asian children.
Topics: Child; Cohort Studies; Fatty Liver; Humans; Kynurenine; Metabolic Syndrome; Overweight; Pediatric Ob | 2022 |
Kynurenine-Induced Aryl Hydrocarbon Receptor Signaling in Mice Causes Body Mass Gain, Liver Steatosis, and Hyperglycemia.
Topics: Animals; Fatty Liver; Hyperglycemia; Kynurenine; Liver; Mice; Receptors, Aryl Hydrocarbon; Signal Tr | 2021 |
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health.
Topics: Animals; Diabetes Mellitus, Type 2; Fatty Liver; Gastrointestinal Microbiome; Health; Humans; Indole | 2018 |
Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1.
Topics: Adiposity; Animals; Azo Compounds; Benzoflavones; Diet, Western; Fatty Liver; Hepatocytes; Indoleami | 2016 |
L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin.
Topics: Adenoviridae; Animal Feed; Animals; Aromatic-L-Amino-Acid Decarboxylases; Fatty Liver; Fibrosis; Fru | 2011 |